TrialInternational journal of cancer2015

Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial.

Amir Goldkorn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.